The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Iavelov I.S.

Kafedra klinicheskoĭ kardiologii Rossiĭskogo gosudarstvennogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

Prevention of heart embolic complications in atrial fibrillation: Possibilities of using rivaroxaban

Authors:

Iavelov I.S.

More about the authors

Journal: Therapeutic Archive. 2013;85(12): 119‑126

Read: 820 times

Download PDF (RU)
Contact the author
Table of contents

PREVENTION OF HEART EMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION: POSSIBILITIES OF USING RIVAROXABAN
PREVENTION OF HEART EMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION: POSSIBILITIES OF USING RIVAROXABAN

To cite this article:

Iavelov IS. Prevention of heart embolic complications in atrial fibrillation: Possibilities of using rivaroxaban. Therapeutic Archive. 2013;85(12):119‑126. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
In-hospital resu­lts of thoracoscopic box-lesion radiofrequency left atrial abla­tion for atrial fibrillation. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(5):483-488
Predictors and impact of myocardial injury (VARC-3 criteria) after transcatheter aortic valve implantation. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(5):489-498
A modi­fied method of left atrial radiofrequency abla­tion for atrial fibrillation in a patient unde­rgoing mitral valve replacement under warm blood cardioplegia. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(5):556-560
Predictors of atrial fibrillation recu­rrence after biatrial cryo-maze procedure: a systematic review. Piro­gov Russian Journal of Surgery. 2024;(11):100-104
Myocardial infa­rction in young age. Russian Journal of Preventive Medi­cine. 2024;(11):77-84
Imme­diate outcomes of simu­ltaneous Cox-Maze procedure in patients with isolated and multivalvular heart defe­cts via right mini-thoracotomy. Piro­gov Russian Journal of Surgery. 2024;(12-2):18-24
Imme­diate and long-term resu­lts of the simu­ltaneous rhythm-converting procedure Cox-Maze IV in multivalvular correction. Piro­gov Russian Journal of Surgery. 2024;(12-2):25-34
Effi­ciency of complex medi­cal reha­bilitation after pulmonary enda­rterectomy. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(6):629-636
Cryoballoon abla­tion combined with antiarrhythmic therapy for atrial fibrillation in patients with cardiovascular como­rbidities. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(6):670-676
Stroke: current state of the problem. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):7-18
Abstract:

The review analyzes the role of atrial fibrillation concurrent with stable manifestations of coronary heart disease when novel oral anticoagulants are used. It gives the results of comparison of the efficacy and safety of warfarin and rivaroxaban in such patients in the large controlled ROCKET-AF trial.

Keywords:

atrial fibrillation
myocardial infarction
oral anticoagulants
warfarin
rivaroxaban

Authors:

Iavelov I.S.

Kafedra klinicheskoĭ kardiologii Rossiĭskogo gosudarstvennogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

Close metadata

References:

  1. You J.J., Singer D.E., Howard P.A. et al. Antithrombotic Therapy for Atrial Fibrillation. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl): e531S-e575S.
  2. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
  3. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012: doi:10.1093/eurheartj/ehs2.
  4. Hart R.G., Benavente O., McBride R., Pearce L.A. Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation: A Meta-Analysis. Ann Intern Med 1999; 131: 492-501.
  5. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. Ann Intern Med 2007; 146: 857-867.
  6. Connolly S.J., Eikelboom J., Joyner C. et al., for the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-817.
  7. The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet 2006; 367: 1903-1912.
  8. Hohnloser S.H., Pajitnev D., Pogue J. et al., for the ACTIVE W Investigators. Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy. An ACTIVE W Substudy. JACC 2007; 50; 2156-2161.
  9. Heidbuche H., Verhamme P., Alings M. et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-651.
  10. Granger C.B., Alexander J.H., McMurray J.J. et al., for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
  11. Connolly S.J., Connolly S.J., Ezekowitz M.D. et al., for the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1351.
  12. Patel M.R., Mahaffey K.W., Garg J. et al., for the ROCKET-AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
  13. Nieuwlaat R., Capucci A., Camm A.J. et al., on behalf of the Euro Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC Member Countries The Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: 2422-2434.
  14. Nabauer M., Gerth A., Limbourg T. et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009; 11: 423-434.
  15. Kakkar A.K., Mueller I., Bassand J.-P. et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J 2012; 163: 13-19.
  16. Alberts1 M.J., Bhatt D.L., Mas J.-L. et al., for the REduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J 2009; 30: 2318-2326.
  17. Yavelov I.S. Antitromboticheskie preparaty v profilaktike tromboembolicheskikh oslozhnenii posle ostrogo koronarnogo sindroma. Aterotromboz 2013; 1: 82-104.
  18. Lip G.Y. H., Huber K., Andreotti F. et al. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting. A Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association [EHRA] and the European Association of Percutaneous Cardiovascular Interventions [EAPCI]. Thromb Haemost 2010; 103: 13-28.
  19. Dans A.L., Connolly S.J., Wallentin L. et al. Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. Circulation 2013; 127: 634-640.
  20. Hohnloser S.H., Oldgren J., Yang S. et al. Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial. Circulation 2012; 125: 669-676.
  21. Mahaffey K.W., White H.D., Nessel C.C. et al., on behalf of the ROCKET AF Investigators. Ischemic Cardiac Outcomes in Patients with AF Treated with Vitamin K Antagonism or Factor Xa Inhibition: Results from the ROCKET AF Trial. Presented at the Scientific Sessions AHA 2011, Orlando: abstract 13492. Dostupno v Internet po adresu http://www.abstractsonline.com/plan/ViewAbstract.aspx&mID=2654&sKey=90b94d15-4a30-4d57-
  22. Patel M.R., Hellkamp A.S., Lokhnygina Y. et al. Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. Analysis From the ROCKET AF Trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). JACC 2013; 61: 651-658.
  23. Mega J.L., Braunwald E., Mohanavelu S. et al., on behalf of the ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomized, double-blind, phase II trial. Lancet 2009; 374: 29-38.
  24. Gibson C.M., Chakrabarti A.K., Mega J. et al., for the ATLAS ACS 2-TIMI 51 Investigators. Reduction of Stent Thrombosis in Patients with Acute Coronary Syndrome Treated with Rivaroxaban in ATLAS ACS 2-TIMI 51. JACC 2013: DOI: 10.1016/j.jacc.2013.03.041.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.